NM  Vol.4 No.4 , December 2013
Affinity Crosslinking of Y1036 to Nerve Growth Factor Identifies Pharmacological Targeting Domain for Small Molecule Neurotrophin Antagonists
ABSTRACT

Classically, small molecule antagonists have targeted membrane bound receptors and intracellular enzyme targets. While this drug discovery strategy is extremely successful, the number of new chemical entities in the pharmaceutical pipeline is diminishing and complementary strategies are in need. A particularly attractive therapeutic strategy is to neutralize soluble signalling proteins using small molecules. Small molecule-based technologies have the potential to sufficiently alter the molecular topology of a given ligand and inhibit ligand/receptor interactionseffectively neutralizing the ligand’s signalling capacity. Recent technical advances in the field of structural biology have enabled the elucidation of ligand/receptor complexes at atomic resolution enabling a detailed appreciation of the molecular interactions governing ligand-mediated receptor activation. Exploiting molecular modeling techniques to study these signalling complexes allows for a paradigm shift from receptorcentric to ligandcentric screening strategies. Nerve growth factor (NGF) is a prototypical protein signalling ligand, which binds two receptors, TrkA and p75NTR. We first explore the molecular landscape governing the ligand/receptor interactions of NGF/TrkA and NGF/p75 structures. Next, we use the recently reported NGF neutralizing small-molecule, Y1036, as an affinity probe to determine residues in proximity to the pharmacological targeting domain of NGF and perform theoretical docking experiments to predict the residues which comprise distinct pharmacological targeting domains on the surface of NGF. Exploiting such strategies may facilitate ligandcentric drug discovery and could further the development of a trophic-factor-selective compound such as a BDNF-selective antagonist.


Cite this paper
J. Eibl, Z. Abdallah, A. Kennedy, J. Scott and G. Ross, "Affinity Crosslinking of Y1036 to Nerve Growth Factor Identifies Pharmacological Targeting Domain for Small Molecule Neurotrophin Antagonists," Neuroscience and Medicine, Vol. 4 No. 4, 2013, pp. 290-298. doi: 10.4236/nm.2013.44043.
References
[1]   B. Munos, “Lessons from 60 Years of Pharmaceutical Innovation,” Nature Reviews Drug Discovery, Vol. 8, No. 12, 2009, pp. 959-968. http://dx.doi.org/10.1038/nrd2961

[2]   P. Imming, C. Sinning and A. Meyer, “Drugs, Their Targets and the Nature and Number of Drug Targets,” Nature Reviews Drug Discovery, Vol. 5, No. 10, 2006, pp. 821-834. http://dx.doi.org/10.1038/nrd2132

[3]   S. Paul, “Steven Paul,” Nature Reviews Drug Discovery, Vol. 8, No. 1, 2009, p. 14.
http://dx.doi.org/10.1038/nrd2800

[4]   M. V. Chao, R. Rajagopal and F. S. Lee, “Neurotrophin Signalling in Health and Disease,” Clinical Science (London), Vol. 110, 2006, pp. 167-173.
http://dx.doi.org/10.1042/CS20050163

[5]   X. L. He and K. C. Garcia, “Structure of Nerve Growth Factor Complexed with the Shared Neurotrophin Receptor p75,” Science, Vo. 304, No. 5672, 2004, pp. 870-875.
http://dx.doi.org/10.1126/science.1095190

[6]   T. Wehrman, X. He, B. Raab, A. Dukipatti, H. Blau and K. C. Garcia, “Structural and Mechanistic Insights into Nerve Growth Factor Interactions with the TrkA and p75 Receptors,” Neuron, Vol. 53, No. 1, 2007, pp. 25-38.
http://dx.doi.org/10.1016/j.neuron.2006.09.034

[7]   D. W. Sah, M. H. Ossipo and F. Porreca, “Neurotrophic Factors as Novel Therapeutics for Neuropathic Pain,” Nature Reviews Drug Discovery, Vol. 2, No. 6, 2003, pp. 460-472. http://dx.doi.org/10.1038/nrd1107

[8]   A. Dray, “Neuropathic Pain: Emerging Treatments,” British Journal of Anaesthesia, Vol. 101, No. 1, 2008, pp. 48-58. http://dx.doi.org/10.1093/bja/aen107

[9]   J. B. Owolabi, G. Rizkalla, A. Tehim, G. M. Ross, R. J. Riopelle, R. Kamboj, M. Ossipov, D. Bian, S. Wegert, F. Porreca and D. K. Lee, “Characterization of Antiallodynic Actions of ALE-0540, a Novel Nerve Growth Factor Receptor Antagonist, in the Rat,” Journal of Pharmacology and Experimental Therapeutics, Vol. 289, 1999, pp. 1271-1276.

[10]   O. Niederhauser, M. Mangold, R. Schubenel, E. A. Kusznir, D. Schmidt and C. Hertel, “NGF Ligand Alters NGF Signaling via p75(NTR) and trkA,” Journal of Neuroscience Research, Vol. 61, No. 3, 2000, pp. 263-272.
http://dx.doi.org/10.1002/1097-4547(20000801)61:3<263::AID-JNR4>3.0.CO;2-M

[11]   K. Spiegel, D. Agrafiotis, B. Caprathe, R. E. Davis, M. R. Dickerson, J. H. Fergus, T. W. Hepburn, J. S. Marks, M. Van Dorf, D. M. Wieland, et al., “PD 90780, a Non Peptide Inhibitor of Nerve Growth Factor’s Binding to the P75 NGF Receptor,” Biochemical and Biophysical Research Communications, Vol. 217, No. 2, 1995, pp. 488-494. http://dx.doi.org/10.1006/bbrc.1995.2802

[12]   J. K. Eibl, S. A. Chapelsky and G. M. Ross, “Multipotent Neurotrophin Antagonist Targets Brain-Derived Neurotrophic Factor and Nerve Growth Factor,” Journal of Pharmacology and Experimental Therapeutics, Vol. 332, No. 2, 2010, pp. 446-454.
http://dx.doi.org/10.1124/jpet.109.159079

[13]   N. Q. McDonald, R. Lapatto, J. Murray-Rust, J. Gunning, A Wlodawer and T. L. Blundell, “New Protein Fold Revealed by a 2.3-A Resolution Crystal Structure of Nerve Growth Factor,” Nature, Vol. 354, No. 6352, 1991, pp. 411-414. http://dx.doi.org/10.1038/354411a0

[14]   T. A. Halgren, “Maximally Diagonal Force Constants and Dependent Angle Bending Coordinates II. Implecations for the Design of Emperical Forcefields,” Journal of the American Chemical Society, Vol. 112, No. 12, 1990, pp. 4710-4723. http://dx.doi.org/10.1021/ja00168a015

[15]   A. N. Jain, “Scoring Noncovalent Protein-Ligand Interactions: A Continuous Differentiable Function Tuned to Compute Binding Affinities,” Journal of Computer-Aided Molecular Design, Vol. 10, No. 5, 1996, pp. 427-440.
http://dx.doi.org/10.1007/BF00124474

[16]   M. M. Berg, D. W. Sternberg, L. F. Parada and M. V. Chao, “K-252a Inhibits Nerve Growth Factor-Induced trk Proto-Oncogene Tyrosine Phosphorylation and Kinase Activity,” The Journal of Biological Chemistry, Vol. 267, 1992, pp. 13-16.

[17]   B. Knusel and F. Hefti, “K-252 Compounds: Modulators of Neurotrophin Signal Transduction,” Journal of Neurochemistry, Vol. 59, No. 6, 1992, pp. 1987-1996.
http://dx.doi.org/10.1111/j.1471-4159.1992.tb10085.x

[18]   B. Lippa, J. Morris, M. Corbett, T. A. Kwan, M. C. Noe, S. L. Snow, T. G. Gant, M. Mangiaracina, H. A. Coffey, B. Foster, E. A. Knauth and M. D. Wessel, “Discovery of Novel Isothiazole Inhibitors of the TrkA Kinase: Structure-Activity Relationship, Computer Modeling, Optimization, and Identification of Highly Potent Antagonists,” Bioorganic & Medicinal Chemistry Letters, Vol. 16, No. 13, 2006, pp. 3444-3448.
http://dx.doi.org/10.1016/j.bmcl.2006.04.003

[19]   J. J. Watson, S. J. Allen and D. Dawbarn, “Targeting Nerve Growth Factor in Pain: What Is the Therapeutic Potential?” BioDrugs, Vol. 22, No. 6, 2008, pp. 349-359.
http://dx.doi.org/10.2165/0063030-200822060-00002

[20]   S. M. Massa, T. Yang, Y. Xie, J. Shi, M. Bilgen, J. N. Joyce, D. Nehama, J. Rajadas and F. M. Longo, “Small Molecule BDNF Mimetics Activate TrkB Signaling and Prevent Neuronal Degeneration in Rodents,” Journal of Clinical Investigation, Vol. 120, No. 5, pp. 1774-1785.
http://dx.doi.org/10.1172/JCI41356

[21]   F. M. Longo and S. M. Massa, “Small Molecule Modulation of p75 Neurotrophin Receptor Functions,” CNS & Neurological Disorders—Drug Targets, Vol. 7, No. 7, 2008, pp. 63-70.
http://dx.doi.org/10.2174/187152708783885093

[22]   F. Brahimi, A. Malakhov, H. B. Lee, M. Pattarawarapan, L. Ivanisevic, K. Burgess and H. U. Saragovi, “A Peptidomimetic of NT-3 Acts as a TrkC Antagonist,” Peptides, Vol. 30, No. 10, 2009, pp. 1833-1839.
http://dx.doi.org/10.1016/j.peptides.2009.07.015

[23]   D. Chen, F. Brahimi, Y. Angell, Y. C. Li, J. Moscowicz, H. U. Saragovi and K. Burgess, “Bivalent Peptidomimetic Ligands of TrkC Are Biased Agonists and Selectively Induce Neuritogenesis or Potentiate Neurotrophin-3 Trophic Signals,” ACS Chemical Biology, Vol. 4, No. 9, 2009, pp. 769-781. http://dx.doi.org/10.1021/cb9001415

[24]   S. Covaceuszach, A. Cassetta, P. V. Konarev, S. Gonfloni, R. Rudolph, D. I. Svergun, D. Lamba and A. Cattaneo, “Dissecting NGF Interactions with TrkA and p75 Receptors by Structural and Functional Studies of an Anti-NGF Neutralizing Antibody,” Journal of Molecular Biology, Vol. 381, No. 4, 2008, pp. 881-896.
http://dx.doi.org/10.1016/j.jmb.2008.06.008

[25]   M. Vilar, I. Charalampopoulos, R. S. Kenchappa, A. Simi, E. Karaca, A. Reversi, S. Choi, M. Bothwell, I. Mingarro, W. J. Friedman, G. Schiavo, P. I. Bastiaens, P. J. Verveer, B. D. Carter and C. F. Ibanez, “Activation of the p75 Neurotrophin Receptor through Conformational Rearrangement of Disulphide-Linked Receptor Dimers,” Neuron, Vol. 62, No. 1, 2009, pp. 72-83.
http://dx.doi.org/10.1016/j.neuron.2009.02.020

[26]   Y. Gong, P. Cao, H. J. Yu and T. Jiang, “Crystal Structure of the Neurotrophin-3 and p75NTR Symmetrical Complex,” Nature, Vol. 454, 2008, pp. 789-793.

[27]   D. Feng, T. Kim, E. Ozkan, M. Light, R. Torkin, K. K. Teng, B. L. Hempstead and K. C. Garcia, “Molecular and Structural Insight into proNGF Engagement of p75NTR and Sortilin,” Journal of Molecular Biology, Vol. 396, No. 4, 2010, pp. 967-984.
http://dx.doi.org/10.1016/j.jmb.2009.12.030

[28]   P. A. Barker, “High Affinity Not in the Vicinity?” Neuron, Vol. 53, No. 1, 2007, pp. 1-4.
http://dx.doi.org/10.1016/j.neuron.2006.12.018

[29]   G. M. Ross, I. L. Shamovsky, G. Lawrance, M. Solc, S. M. Dostaler, D. F. Weaver and R. J. Riopelle, “Reciprocal Modulation of TrkA and p75NTR Affinity States Is Mediated by Direct Receptor Interactions,” European Journal of Neuroscience, Vol. 10, No. 3, 1998, pp. 890-898.
http://dx.doi.org/10.1046/j.1460-9568.1998.00094.x

 
 
Top